<div><div></div><div>Mira Pharmaceuticals reported no revenues for the year ended December 31, 2025 and recorded a net loss of $10.44 million, equivalent to a basic and diluted loss per share of $1.35. The company did not present gross profit separately; total operating costs were $10.493 million, driven by general and administrative expenses and research and development. The filing outlines ongoing clinical progress for ketamine-derived assets and recent pipeline expansion through acquisition activity. Financial Highlights <ul><li>Revenue: $—, no revenues reported for the years ended December 31, 2025 and 2024.</li><li>Operating income: $(10.49) million, presented as Total operating costs of $10.493 million (General &amp; Administrative $8.773 million; Research &amp; Development $1.720 million).</li><li>Net income: $(10.44) million, reported as Net Loss for the year ended December 31, 2025.</li><li>Net income per share: $(1.35), reported as basic and diluted loss per share for the year ended December 31, 2025.</li></ul> Business Highlights <ul><li>Clinical program progress: Ketamir-2 single ascending dose (SAD) study completed; multiple ascending dose (MAD) study is underway. A Phase 2a trial in chemotherapy-induced peripheral neuropathy (CIPN) is planned for H1 2026 pending regulatory approvals and site readiness.</li><li>Pipeline expansion: Acquisition of SKNY in September 2025 added SKNY-1 targeting metabolic and behavioral indications, supporting preclinical advancement of the pipeline.</li><li>Regulatory status: The DEA determined Ketamir-2 and MIRA-55 are not controlled substances, which simplifies aspects of development and regulatory management.</li><li>R&amp;D focus and milestones: Preclinical data indicate MIRA-55 has analgesic and anti-inflammatory effects; IND-enabling studies and toxicology work are ongoing to advance clinical readiness.</li></ul>Original SEC Filing: MIRA PHARMACEUTICALS, INC. [ MIRA ] - 10-K - Mar. 31, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

MIRA

Mira Pharmaceuticals reported no revenue for the year ending December 31, 2025, with a net loss of $10.44 million, translating to a loss per share of $1.35. Total operating costs were $10.493 million, primarily due to administrative and R&D expenses. The company is advancing its clinical programs, including a completed SAD study for Ketamir-2 and plans for a Phase 2a trial in 2026. Recent acquisition of SKNY supports pipeline expansion, and regulatory status has been clarified for certain assets.

TradingView

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Mira Pharmaceuticals

VG Health

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

iShares Global Healthcare

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

iShares US Pharma

iShares Biotechnology ETF

SPDR S&P Biotech

Mira Pharmaceuticals 10-K: $— Revenue, $(1.35) EPS, $(10.44) M Net Loss